Nexentis Technologies Inc. (NXTS): Total Assets
$20.41M
As of 2025-12-31
$18.69M
As of 2026-06-30
+46.5%
3-year compound annual growth
+97.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.41M | +273.4% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $5.46M | -24.6% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $7.24M | +11.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.49M | -14.5% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $7.60M | n/m | 2023-03-27, Balance as of period end |
| 2020-12-31 | $687.6K | +3.5% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $664.7K | -22.6% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $859.2K | n/a | 2020-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $20.41M | +273.4% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $20.39M | +29.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $20.78M | +226.4% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $21.06M | +179.3% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $21.08M | +51.4% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $19.53M | +11.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $21.49M | +274.5% |
Compare NXTS, QNRX, EVFM, MENS side by side · Screen every company in Pharmaceutical Preparations ↗